Docket #: S16-360
Methods to identify and treat MYC-driven Renal Cell Carcinoma
Researchers at Stanford have developed methods to identify and treat MYC-driven cancers, including renal cell carcinoma (RCC). RCC is a common, aggressive type of kidney cancer and effective therapeutics are lacking. RCC is often driven by overexpression of the MYC oncogene. Recent work from the inventors has shown that MYC regulates lipogenesis (including fatty acid synthesis) to promote tumorigenesis. With this technology, the inventors identify inhibition of the fatty acid synthesis pathway as a novel therapeutic target for treatment of RCC. In addition, they have developed methods to identify MYC-driven, lipogenesis-dependent cancers. This technology may be used to identify and develop more effective therapeutics to treat RCC.
Stage of research
Using their MYC-driven RCC mouse model, the inventors have shown that inhibiting the fatty acid synthesis pathway prevents tumorigenesis and cancer progression.
Applications
- Therapeutic development for MYC-driven cancers, including RCC
Advantages
- Helps solve an unmet need- potential to develop new, effective RCC therapeutics
- New therapeutic target for treatment of RCC
Publications
- PCT Patent Applicaton Publication No. WO2018170316A1.
Related Links
Patents
- Published Application: WO2018170316.
- Published Application: 20210137934
Similar Technologies
-
Wnt agonist and antagonists for organoid cultures S18-270Wnt agonist and antagonists for organoid cultures
-
Compounds targeting phospholipid synthesis to treat cancer and metabolic disease S17-409Compounds targeting phospholipid synthesis to treat cancer and metabolic disease
-
An improved CD206 binder for targeted immune checkpoint blockade and delivery to tumor-associated macrophages S23-438An improved CD206 binder for targeted immune checkpoint blockade and delivery to tumor-associated macrophages